Lignin-PLGA Nanoparticles Surfactant-Free Synthesis
Solution Overview
Problem
There is an unmet need for bio-friendly materials with controlled properties and degradation profiles for drug delivery, particularly for triple negative breast cancer treatment, where existing materials face challenges such as low bioavailability, poor targeting, and adverse effects due to the lack of surfactant-free synthesis methods for stable PLGA nanoparticles.
Innovation Solution
The development of lignin-graft-poly(lactic-co-glycolic acid) (PLGA) biopolymer nanoparticles synthesized without surfactants, utilizing alkaline lignin or sodium lignosulfonate, which form amphiphilic biopolymers with tunable properties for improved drug delivery, including enhanced permeability and retention effects and sustained release of therapeutic agents like GDC-0623.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If surfactants are used to make PLGA nanoparticles stable in aqueous suspension, then particle stability is improved, but excess surfactant must be removed by ultrafiltration, dialysis, or ultracentrifugation, adding cost and complexity to synthesis
Solution Approach 1:
The invention extracts and eliminates the surfactant component from the nanoparticle synthesis system. By using PLGA nanoparticles without surfactants, the patent removes the need for surfactant removal steps (ultrafiltration, dialysis, ultracentrifugation), thereby reducing synthesis complexity and cost while maintaining particle stability through alternative stabilization mechanisms inherent to the PLGA polymer matrix
Solution Approach 2:
The PLGA nanoparticles are designed to be self-stabilizing without requiring external surfactant agents. The polymer matrix itself provides the necessary stability in aqueous suspension through its amphiphilic nature and controlled degradation properties, allowing the system to serve its own stabilization function without additional components
2Reliability
If conventional PLGA nanoparticles are used for drug delivery, then biocompatibility is maintained, but bioavailability and targeting efficiency are limited
Solution Approach 1:
The invention changes key parameters of the nanoparticle system including size distribution, surface charge, and degradation rate to enhance bioavailability and targeting efficiency. By controlling nanoparticle size (typically 50-200 nm), surface charge (zeta potential), and degradation kinetics, the patent achieves improved drug delivery performance while maintaining biocompatibility of the PLGA material
Solution Approach 2:
The patent employs composite nanoparticle formulations that combine PLGA with other biocompatible materials or functionalize the PLGA surface with targeting ligands, hydrophilic coatings, or drug conjugation groups. This composite approach enhances bioavailability and targeting efficiency while preserving the inherent biocompatibility of the base PLGA polymer
3Object-affected harmful factors
If triple negative breast cancer is treated with conventional chemotherapy, then tumor cells are attacked, but adverse effects such as peripheral neuropathy, febrile neutropenia, and cardiovascular disease occur
Solution Approach 1:
The invention segments the drug delivery system into targeted nanoparticles that deliver chemotherapy agents specifically to tumor cells. By using PLGA nanoparticles with controlled size, surface properties, and degradation profiles, the patent enables localized drug release at the tumor site, reducing systemic exposure and thereby minimizing adverse effects such as peripheral neuropathy, febrile neutropenia, and cardiovascular disease while maintaining effective cancer cell killing
Solution Approach 2:
The PLGA nanoparticle acts as an intermediary carrier that mediates between the chemotherapy drug and the tumor target. This intermediary system protects the drug during circulation, enables targeted delivery to triple negative breast cancer cells, and controls release kinetics, thereby reducing off-target toxicity and adverse effects while maintaining therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lignin-PLGA nanoparticles demonstrate improved bioavailability and efficacy against triple negative breast cancer cells, with enhanced cellular uptake and sustained drug release, reducing adverse effects and improving treatment outcomes compared to conventional PLGA nanoparticles.
Implementation Method 1
In an aqueous environment, the hydrophobic PLGA tends to associate in the core of the nanoparticles, and the hydrophilic lignin tends to associate on the surface of the nanoparticles
Implementation Method 2
The nanoparticles may be formed either by self-assembly or by an emulsion-evaporation process
Data Source
AI summary
Amphiphilic biopolymers have been synthesized by grafting lignin onto PLGA to form graft polymers, which can then be further assembled into polymeric nanoparticles without a requirement for surfactants. The nanoparticles have a typical diameter of 75 nm. The nanoparticles may be used, for example, for drug delivery, including efficient and effective drug delivery against cancers such as triple negative breast cancers.